An Introduction to EATRIS, Europe’s Translational Research Infrastructure for Translational Medicine
An open seminar by EATRIS Operations Director Anton Ussi.
We invite researchers from academia, startups and SMEs developing potential medicinal and/or diagnostic products to attend. Learn how EATRIS can support you in advancing your project along the challenging development path to reach the patient (from preclinical to early clinical stages).
Coffee & cake will be served!
More about EATRIS
EATRIS ERIC is a European research infrastructure designed to accelerate the development of new drug treatments, diagnostic tools and other medical products. EATRIS acts as a "distributed infrastructure" built up of 13 member countries and more than 90 academic research centers across Europe with the headquarter located in Amsterdam.
EATRIS works within five focus areas (platforms): Biomarkers, Advanced Therapeutic Medicinal Products (ATMPs), Diagnostics and Medical Imaging (Imaging & Tracing), Small Molecules and Vaccines.
The Norwegian EATRIS participation is shared between the University of Oslo (UiO), the University of Bergen (UiB), Norwegian University of Science and Technology (NTNU), the Artic University of Norway (UiT) and the four Regional Health Authorities in Southeastern, Western, Central and Northern Norway.
For Norwegian researchers, the membership opens up an international window for collaboration with industry and academia, an increased opportunity for exposure of the Norwegian expertise, and the possibility of professional interaction across traditional borders.
During the seminar, Anton Ussi, Operations & Finance Director at EATRIS Coordination & Support (Amsterdam) will present EATRIS and the opportunities offered to researchers. Anton Ussi will introduce the “EATRIS plus” project, a four-year Horizon 2020 project which recently received funding and aims to use the EATRIS capacities in its 13 European countries to create a multi-omic tool box that will support the development of patient-targeted interventions based on cross-omic profiles.